Evidence map›Paper›PMID 35733077›Full record

ArticleEuropean journal of drug metabolism and pharmacokinetics2022

Evaluation of an Ussing Chamber System Equipped with Rat Intestinal Tissues to Predict Intestinal Absorption and Metabolism in Humans.

Chi Guan, Yingxin Yang, Dong Tian, Zhiqiang Jiang, Huiying Zhang, Yali Li, Jiaxiu Yan, Congman Zhang, Chun Chen, Junhua Zhang and 5 more

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of drug metabolism and pharmacokinetics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Chi GuanDrug Metabolism and Pharmacokinetics (DMPK) Department, Pharmaron Beijing Co., Ltd., 6 Taihe Road, BDA, Beijing, 100176, China.
Yingxin YangDrug Metabolism and Pharmacokinetics (DMPK) Department, Pharmaron Beijing Co., Ltd., 6 Taihe Road, BDA, Beijing, 100176, China.
Dong TianDrug Metabolism and Pharmacokinetics (DMPK) Department, Pharmaron Beijing Co., Ltd., 6 Taihe Road, BDA, Beijing, 100176, China.
Zhiqiang JiangDrug Metabolism and Pharmacokinetics (DMPK) Department, Pharmaron Beijing Co., Ltd., 6 Taihe Road, BDA, Beijing, 100176, China.
Huiying ZhangDrug Metabolism and Pharmacokinetics (DMPK) Department, Pharmaron Beijing Co., Ltd., 6 Taihe Road, BDA, Beijing, 100176, China.
Yali LiDrug Metabolism and Pharmacokinetics (DMPK) Department, Pharmaron Beijing Co., Ltd., 6 Taihe Road, BDA, Beijing, 100176, China.
Jiaxiu YanDrug Metabolism and Pharmacokinetics (DMPK) Department, Pharmaron Beijing Co., Ltd., 6 Taihe Road, BDA, Beijing, 100176, China.
Congman ZhangDrug Metabolism and Pharmacokinetics (DMPK) Department, Pharmaron Beijing Co., Ltd., 6 Taihe Road, BDA, Beijing, 100176, China.
Chun ChenDrug Metabolism and Pharmacokinetics (DMPK) Department, Pharmaron Beijing Co., Ltd., 6 Taihe Road, BDA, Beijing, 100176, China.
Junhua ZhangDrug Metabolism and Pharmacokinetics (DMPK) Department, Pharmaron Beijing Co., Ltd., 6 Taihe Road, BDA, Beijing, 100176, China.
Jing WangDrug Metabolism and Pharmacokinetics (DMPK) Department, Pharmaron Beijing Co., Ltd., 6 Taihe Road, BDA, Beijing, 100176, China.
Yu WangDrug Metabolism and Pharmacokinetics (DMPK) Department, Pharmaron Beijing Co., Ltd., 6 Taihe Road, BDA, Beijing, 100176, China.
Hongwen DuDrug Metabolism and Pharmacokinetics (DMPK) Department, Pharmaron Beijing Co., Ltd., 6 Taihe Road, BDA, Beijing, 100176, China.
Hongyu ZhouDrug Metabolism and Pharmacokinetics (DMPK) Department, Pharmaron Beijing Co., Ltd., 6 Taihe Road, BDA, Beijing, 100176, China.
Tao WangDrug Metabolism and Pharmacokinetics (DMPK) Department, Pharmaron Beijing Co., Ltd., 6 Taihe Road, BDA, Beijing, 100176, China. tao.wang@pharmaron.com.ORCID http://orcid.org/0000-0002-2620-5077

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectiveOral bioavailability (F) is one of the key factors that need to be determined in drug discovery. This factor is determined by the permeability and solubility of new molecule entities (NMEs) according to the biopharmaceutics classification system (BCS).

methodsIn the present study, we evaluated the permeability of 22 drugs in rat intestinal tissues using an Ussing chamber system and correlated the permeability with data on human intestinal absorption (F

resultsThe rat intestinal permeability data were better correlated with the combined effect of the absorbed fraction (F

conclusionAn Ussing chamber system incorporating rat intestinal tissue would be a valuable tool to predict human intestinal absorption and metabolism for molecules with various physicochemical properties.

Indexed as

Intestinal AbsorptionIntestinal MucosaAnimalsBiological TransportHumansIntestinesPermeabilityRats

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.